19
Aug
New Nitrosamine Impurity Issue - Lachman Blog

FDA Notes the Emergence of a New Nitrosamine Impurity Issue and Requests Data

Yesterday, the FDA quietly posted another update to the CDER Nitrosamine Impurity Acceptable Intake Limits webpage. The latest update is not an extended timeline for submitting changes or new acceptable intake (AI) limits as might be expected but instead because CDER has become aware of an emerging issue related to small-molecule nitrosamine impurities such as […]

Read More
18
Aug
Ready, Set, Pay - Lachman Blog - FDA PDUFA

Ready, Set, Pay!

The FDA announced today (here) that FY 2026 prescription drug program fee invoices for New Drugs have been sent out to firms via email. The Agency asks firms to review the invoices promptly and report any discrepancies that might arise. Prescription drug program fees must be paid for up to five strengths of a product approved […]

Read More
07
Aug

Embracing QRM Principles

I recently had the honour to be invited to speak at the PDA India’s annual conference in Hyderabad. The event was well supported by the local India office of FDA in person and senior FDA personnel (including Carmela Rosa and Jose Melendez amongst others) virtually. It was great to see the FDA continue to support […]

Read More
01
Aug
toy Monarch butterfly emerging from its chrysalis.

Protocol Design and Lifecycle Following the Draft ICH Stability Guidance

  As discussed in a recent Lachman blog Revised Q1 Draft Stability Document Issued by FDA, the draft guidance titled Q1 Stability Testing of Drug Substances is a consolidated revision of ICH Q1A(R2), Q1B, Q1C, Q1D, Q1E, and Q5C.  This draft guidance provides guidance on product categories, such as advanced therapy medicinal products, vaccines, and other […]

Read More
23
Jul
Lightning discharges during a large rainstorm in a city with forest fringes

Some Additional Light Shed on Commissioner’s National Priority Voucher Program

On July 22, 2025, the FDA announced more details on the CNPV pilot program (here), indicating that the Agency will accept no more than five applications for the first year (2025).  The announcement provides a broad program overview along with key program benefits. The announcement also outlines the eligibility criteria for inclusion, stating: “Your company […]

Read More
14
Jul
instrument medicine

Petition Filed Regarding Rational Expiration Dates of Medications

In combing through regulations.gov this morning, I found a July 7, 2025 petition (here) submitted by a physician citing concerns about “prematurely expiring drugs.”  His point is that many drugs likely would still meet all of the required specifications outlined in an application well past their labeled expiration dates, which could positively impact drug shortages and […]

Read More
26
Jun
Rx Prescribing Information Bill Also Introduced in the House - Lachman Blog

Rx Prescribing Information Bill Also Introduced in the House

On June 25, 2025, Reps. Sherrill and Harshbarger reintroduced a bipartisan bill to modernize prescription information (here) and, on June 12, 2025, two senators introduced a similar bill in the Senate (see previous post here). Now we have very similar bills floating around in each chamber. Maybe this is the year that the legislation will pass […]

Read More
1 … 6 7 8 … 35